![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden. Decision-making to treat in the frontline is based on histology, disease burden and patient symptoms. The general approach should be a combination of rituximab and chemotherapy, traditionally using alkylating agents, with or without an anthracycline, with more recent evidence for the alternative of bendamustine. Relapsed/refractory follicular lymphoma carries similar variability in presentation. Therapeutic options include the same regimens traditionally used for first-line therapy; however, they also include agents, such as bendamustine, bortezomib, lenalidomide and anti-CD20 agents (rituximab, ofatumumab and radioimmunotherapy). Finally, hematopoietic stem cell transplantation (both autologous and allogeneic) remains a useful treatment strategy, although the optimal timing of such approaches requires further clarification.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.